Literature DB >> 19038765

Part II: Liver function in oncology: towards safer chemotherapy use.

Kathryn M Field1, Michael Michael.   

Abstract

The liver is fundamentally important in drug metabolism. In oncology, the astute clinician must not only understand the meaning and limitations of commonly ordered liver biochemical tests, but also be aware of which anticancer agents might induce liver dysfunction, and of the strategies for appropriate dosing of patients with pre-existing liver dysfunction. In part I of our Review, we highlighted both the importance and inadequacies of identifying serum biochemical liver abnormalities in oncology; we also discussed a lack of routine formal investigation of liver function. We summarised chemotherapy-related hepatotoxicity and other causes of liver toxic effects in patients with cancer. Here in part II, we discuss trials that have specifically assessed chemotherapy dosing strategies in the setting of overt biochemical liver dysfunction and we note their recommendations. Furthermore, we review other assessments of liver metabolic and excretory function, particularly in the setting of chemotherapy drug handling. We discuss the potential use of these metabolic probes in practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19038765     DOI: 10.1016/S1470-2045(08)70307-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  23 in total

1.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

Review 2.  Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers.

Authors:  Samdeep K Mouli; Ramona Gupta; Neil Sheth; Andrew C Gordon; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

3.  Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus.

Authors:  Kohei Shitara; Tomoya Yokota; Setsuo Utsunomiya
Journal:  Gastrointest Cancer Res       Date:  2009-07

4.  Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation.

Authors:  Sadayuki Kawai; Yasuhiro Sakamoto; Yoshikazu Takahashi; Sonoko Ichikawa; Makio Gamoh
Journal:  J Gastrointest Cancer       Date:  2015-12

5.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

6.  Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy.

Authors:  Yasoo Sugiura; Etsuo Nemoto; Osamu Kawai; Yasuyuki Ohkubo; Hisae Fusegawa; Shizuka Kaseda
Journal:  Lung Cancer (Auckl)       Date:  2013-06-08

7.  A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats.

Authors:  Seigo Hiratani; Ryutaro Mori; Yohei Ota; Ryusei Matsuyama; Takafumi Kumamoto; Yoji Nagashima; Daisuke Morioka; Itaru Endo
Journal:  In Vivo       Date:  2019 May-Jun       Impact factor: 2.155

8.  How I treat hepatitis C virus infection in patients with hematologic malignancies.

Authors:  Harrys A Torres; George B McDonald
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

9.  Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer.

Authors:  Urs Zingg; Jens Forberger; Branimir Rajcic; Christopher Langton; Glyn G Jamieson
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

10.  Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study.

Authors:  Andry Van de Louw; Kathleen Twomey; Nicholas Habecker; Kevin Rakszawski
Journal:  Ann Hematol       Date:  2020-09-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.